Table 1.
The characteristics of the involved studies
| First authors/published year | Country | No. | Disease etiology | Study design | Cell source | Cell dosage | Injection rout | Sex (male/female) | Age (years) | End-point of observation | Quality | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SCT | SMT | SCT | SMT | ||||||||||
| Ming Shi/2012 | China | 43 | HBV-ACLF | RCT | UC-MSCs | Each 0.5 × 106/kg, thrice | PV | 20/4 | 15/4 | 40 (24–59) | 45 (26–62) | 18 months | High |
| Bing-liang Lin/2017 | China | 110 | HBV-ACLF | RCT | BM-MSCs | 1.0 to 10 × 105 cells/kg for 4 weeks | PV | 53/3 | 51/3 | 42.8 ± 8.4 | 40.0 ± 9.9 | 24 weeks | High |
| Zheng Zhang/2012 | China | 45 | HBV with decompensated LC | Open-labeled, paired, controlled study, CT | UC-MSCs | Each 0.5 × 106/kg in NS, once every 4 weeks three times | PV | 14/1 | 26/4 | 48 (25–64) | 47 (29–64) | 12 months | Low |
| Mehdi Mohamadnejad/2013 | Iran | 25 | Decompensated LC (cirrhosis cryptogenic 11, PBC 2, HBV 2, HCV 1, AIH 9) | RCT | BM-MSCs | Median of 195 million (120–295 million) in 100 mL NS | PV | 7/7 | 6/5 | 43.1 ± 17.6 | 34.6 ± 13.8 | 12 months | Moderate |
| Liang Peng/2011 | China | 158 | LF caused by HBV | Retrospective case control study | BM-MSCs | In 10 mL of NS | HA | 50/3 | 99/6 | 42.19 ± 10.8 | 42.22 ± 11.37 | 48 weeks | Very low |
| Yang-Qiu Bai/2014 | China | 47 | Decompensated LC (43 HBV) | Prospective CT | BM-MNCs | 1.0–11.2 × 1010/L | HA | 20/12 | 9/6 | 46.4 ± 11.6 | 47.4 ± 11.1 | 24 months | Very low |
| Laurent Spahr/2013 | Switzerland | 58 | Decompensated ALD (all with cirrhosis, 81% with alcoholic steatohepatitis | RCT | BM-MNCs | 4.7 × 107/kg | HA | 24/4 | 20/10 | 54 (34–66) | 56 (37–68) | 3 months | Moderate |
| Qinzhi Deng/2015 | China | 70 | HBV-related decompensated cirrhosis | Prospective study | APBSC | 2–4 × 107 | HA | 20/13 | 12/23 | 49.48 ± 11.07 | 50.20 ± 10.64 | 48 weeks | Low |
| Mehdi Mohamadnejad/2016 | Iran | 27 | Decompensatedcirrhosis | RCT | BM-MNCs | 20 mL of serum | PV | 12/6 | 5/4 | 43.90 ± 14.84 | 46.22 ± 15.31 | 6 months | Moderate |
| Yu-Hua Li/2016 | China | 45 | HBV-ACLF | Prospective study | UC-MSCs | 100 × 106 cells in 60 mL of NS | HA | 8/3 | 26/8 | 51.1 ± 11.2 | 50.0 ± 10.9 | 24 months | Very low |
PBC primary biliary cirrhosis, HBV hepatitis B virus, HCV hepatitis C virus, AIH autoimmune hepatitis, BM-MNCs bone marrow mononuclear cells, HA hepatic artery, MSC mesenchyme stem cell, NA not available, RCT randomized controlled trial, PV peripheral vein